Daily Derm Times: July 21, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Apremilast Shows Promise in Genital Psoriasis

A retrospective case series found that apremilast induced complete remission in 6 men with treatment-resistant genital psoriasis.

Johnson & Johnson Submits NDA for Icotrokinra in Plaque Psoriasis

Johnson & Johnson submitted an NDA for icotrokinra, a promising new treatment for moderate to severe plaque psoriasis in adults and adolescents.

Fall Clinical PA/NP 2025: PAs and NPs Take Control of Their Future

The 2025 Fall Clinical Dermatology Conference energized PAs and NPs with innovative strategies, addressing burnout, digital branding, and personalized medicine.

FDA Accepts sNDA for Sotyktu in PsA

Bristol Myers Squibb's deucravacitinib gains global regulatory acceptance for treating active psoriatic arthritis, promising a new oral treatment option.

Q&A with Steven Dayan, MD, FACS: Unpacking the Full Impact of Neurotoxins with Patient-Reported Outcomes

According to new research from Steven Dayan, MD, FACS, PROs are reshaping aesthetic medicine, enhancing Botox treatment insights and prioritizing holistic patient care.

Empowering Patients and Families in the Management of Vitiligo

At a recent Dermatology Times Case-Based Roundtable event, Stephanie Simmerman, DNP, APRN-C, discussed treatment selection, access challenges, and more for patients with vitiligo.